Researchers from the University of Central Florida recently received a $400,000 grant from the Juvenile Diabetes Research Foundation, which they will use to create a tube that resists infection and encapsulation and is inserted under the skin for the delivery of insulin via a pump.
Featured
Industry News NOVARTIS CORPORATION: Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
Latest News
Regulatory SAREPTA THERAPEUTICS, INC.: Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
Regulatory SANOFI: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
Federal Issues
AQUESTIVE THERAPEUTICS: Granted Temporary Restraining Order (TRO) Against Alvogen
- PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION: PCMA Supports Legislation to Ensure Patients Pay Lowest Price for Prescription Drugs
- U.S. DEPARTMENT OF HOMELAND SECURITY: DHS Statement on Protecting the Nation from Foreign Terrorist Entry to the United States
- PHARMACEUTICAL CARE MANAGEMENT CARE ASSOCIATION: Federal Circuit Court Unanimously Strikes Down Arkansas Mandate Restricting PBM Tools
- PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION: Congressional Budget Office Score of Medicare Point-of-Sale Rebates Undermines Drugmakers’ Signature Issue
Industry News
SANOFI: Sanofi and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list price
- METAGENICS, INC.: To Launch Personalized Lifestyle Medicine Center (PLMC)
- SAFE RX: Announces Availability in AmerisourceBergen
- SOPHiA GENETICS: Raises $77 Million to Accelerate the Democratization of Data-Driven Medicine
- MYLAN N.V.: Sanofi's Formulation Patents on Multibillion-Dollar Lantus® are Invalidated by U.S. Patent and Trademark Office via IPR, Announces Mylan
Innovation
- ACTINIUM PHARMACEUTICALS: Appoints Qing Liang, PhD, DABR as Vice President, Head of Radiation Sciences to Further Innovation for its AWE Technology Platform and Growing Pipeline of Antibody Radiation Conjugate Therapies
- VAST THERAPEUTICS: Announces Results Showing Ability to Eradicate Anthrax
- SANA BIOTECHNOLOGY: Launches Focusing on Engineering Cells to Create a New Class of Medicines
- CERTARA: US FDA Awards Certara’s Simcyp Division Two New Dermal Virtual Bioequivalence Grants
Regulatory
- SANOFI: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
- MYLAN INC: Announces FDA Approval of Wixela™ Inhub™ (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder)
- SUNOVION PHARMACEUTICALS INC: Receives Complete Response Letter from FDA for Apomorphine Sublingual Film (APL-130277)
- EXELIXIS: Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
Alerts Sign-up